ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1381	National Cancer Institute	Html	en	Skin Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.	skin cancer 0.822138 NMSC lesion reduction 0.586326 skin cancer reduction 0.555393 self-reported midday sun 0.540371 average new lesions 0.584312 Skin Cancer Prevention 0.571287 study attrition rates 0.542607 new actinic keratoses 0.584773 fewer actinic lesions 0.603501 skin cancer—a time 0.536376 daily sunscreen application 0.747804 poor surrogate endpoint 0.539998 6-month post-intervention follow-up 0.542973 fewer new lesions 0.602501 solar keratoses 0.994656 provider-based sun protection 0.532584 sun protection factor 0.548485 Australian randomized study 0.58712 regular sunscreen 0.624027 sunscreen placebo 0.612947 UV radiation exposure 0.5401 clinically normal skin. 0.54962 SCC prevention trials 0.561668	new solar keratoses 0.591696 sun-protective behaviors 0.556779 significantly lower number 0.53979 chemopreventive agent 0.53119 invasive skin cancer 0.584968 community skin cancer 0.550184 population-based longitudinal study 0.568978 significantly greater number 0.537464 placebo group 0.679758 NMSC incidence rates 0.595744 Reduce Actinic Cancer 0.56707 spontaneous regression rate 0.544682 4-month clinical trials 0.540996 randomized controlled trial 0.576053 new lesions 0.702948 randomized trials 0.539994 nicotinamide group 0.630321 base-cream placebo group 0.599568 appearance-based behavioral interventions 0.531285 sun exposure 0.594318 sunscreen group 0.779335 NMSC lesions 0.609075 self-reported sun-protective behaviors 0.541953	CLICK HERE
1427	National Cancer Institute	Html	en	Cancer Pain (PDQ®)–Patient Version	Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed.	pain pathway 0.562753 cancer treatment 0.530419 opioid doses 0.512563 certain older patients 0.494486 blocks pain 0.560936 PDQ cancer information 0.578981 Skin pain 0.59257 pain medicine 0.620891 pain treatment 0.60597 different opioid 0.496343 pain control plan 0.622009 means mild pain 0.593227 cancer information summary 0.53585 bone pain 0.598741 PDQ Cancer Pain 0.631355 patients 0.72567 cancer patients 0.497501 Poor pain 0.553511 NCI PDQ cancer 0.498652 effects 0.513118 radiation therapy 0.594681 patients better pain 0.603263 chronic pain 0.55423 pain control medicine 0.611052 new pain 0.590569	breakthrough pain 0.577542 palliative care 0.539853 Pain relievers 0.575317 pain control 0.678976 Treating Cancer Pain 0.619773 National Cancer Institute 0.532557 commonly used opioid 0.491401 pain relief 0.639394 cancer pain 0.765349 older patients 0.709433 pain 0.970646 current pain treatments 0.604816 healthcare team 0.547409 drugs 0.511492 opioid treatment 0.49086 external radiation therapy 0.506549 intense pain 0.577346 severe pain 0.654451 PDQ summary 0.540695 control pain 0.601004 pain levels 0.579761 means moderate pain 0.593293 pain threshold 0.556519 means severe pain 0.59891	CLICK HERE
1543	National Cancer Institute	Html	en	Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.	red blood cells 0.657008 treatment 0.69838 cancer treatment 0.510853 stored stem cells 0.432024 myeloid stem cell 0.410543 abnormal cells 0.408626 cord). 0.586593 immature blood cells 0.444877 blast cells 0.409519 CNS prophylaxis 0.43336 cancer cells 0.637541 lymphoid stem cell 0.411207 type 0.407802 chemotherapy 0.418061 PDQ cancer information 0.486683 specific cancer cells 0.45646 clinical trial search 0.434142 white blood cells 0.722058 stem cell 0.530795 treatment clinical trials 0.437953 blood stem cells 0.480973 National Cancer Institute 0.448039 clinical trials 0.958798 mature blood cells 0.496196	Natural killer cells 0.443636 normal cells 0.428739 cancer information summary 0.448111 clinical trial 0.624583 new treatment 0.467045 stem cell transplant 0.495713 kinase inhibitor therapy 0.4731 Lymphoblastic Leukemia Treatment 0.414582 chance leukemia cells 0.460746 patients 0.42006 blood cells 0.731186 bone marrow 0.727339 immature cells 0.419809 CAR T-cell therapy 0.438682 cells 0.839029 cancer clinical trials 0.459465 acute lymphoblastic leukemia 0.946164 radiation therapy 0.527726 Treatment Editorial Board 0.410648 cancer 0.8076 standard treatment 0.454915 tyrosine kinase inhibitor 0.516075 leukemia cells 0.619353	CLICK HERE
1605	National Cancer Institute	Html	en	Cervical Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for cervical cancer.	PDQ Screening 0.389933 abnormal cells 0.425615 helpful screening test 0.401855 treatment 0.366742 cancer screening methods 0.422407 Pap test results 0.472434 ongoing clinical trials 0.410435 certain positive Pap 0.459229 screening tests 0.370134 cervical cancer increases 0.4511 HPV test lowers 0.401961 cancer cells 0.382684 Pap smear 0.380615 following PDQ summaries 0.395466 Cancer Information Service 0.388041 human papillomavirus 0.366703 PDQ cancer information 0.504059 false-negative test result 0.373852 Prevention Editorial Board 0.401875 National Cancer Institute 0.462131 clinical trials 0.549883 cervical changes 0.387237 Pap tests 0.380549 false-positive test results 0.375133	cancer information summary 0.450393 Pap test 0.755213 cervix 0.421409 positive Pap test 0.475496 breast cancer prevention 0.377745 Cancer screening trials 0.426144 HPV test 0.524062 cervical cancer screening 0.546179 Cancer Care page 0.38052 cervical cancer 0.937005 PDQ summary 0.376855 HPV DNA test 0.398682 cervical tissue 0.390487 cancer symptoms 0.370983 NCI PDQ cancer 0.416761 HPV infection 0.382279 cells 0.465881 tests 0.403289 cancer information summaries 0.392344 cervical dysplasia 0.41859 comprehensive cancer information 0.393061 HPV infections 0.396784 women 0.413929	CLICK HERE
1615	National Cancer Institute	Html	en	Cardiopulmonary Syndromes (PDQ®)–Health Professional Version	Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.	vena cava 0.611223 pericardial tamponade 0.679952 evidence 0.62034 randomized controlled trials 0.605832 malignant pleural effusion 0.70666 pericardial fluid collection 0.700496 significant pericardial effusions 0.706328 underlying malignant disorders 0.602719 right mainstem bronchus 0.652149 chest 0.626465 cancer patients 0.972375 malignant pericardial effusion. 0.719099 Cancer Dyspnea Scale 0.624114 subxiphoid pericardial windows 0.680282 treatment 0.619895 nonmalignant causes 0.594571 Pericardial biopsy 0.658961 pericardial effusions. 0.666377 pericardial sac. 0.661251 dyspneic cancer patients 0.638184 pericardial sclerosis 0.657248 Pericardial friction rubs 0.684646 subxiphoid pericardial window 0.711885 loculated pleural effusions 0.605868 pericardial effusion 0.810932	pericardial sac 0.692904 advanced lung cancer 0.597362 terminally ill patients 0.609314 large pleural effusion 0.611685 pulmonary function tests 0.594337 Pericardial fluid cytology 0.702526 inoperable cancer patients 0.631248 lung cancer patients 0.649316 Recurrent pericardial effusion 0.706493 dyspnea 0.731471 pericardial masses 0.661922 pericardial fluid reaccumulation 0.694759 pericardial mesothelioma 0.66558 respiratory muscle dysfunction 0.634779 inferior vena cava 0.596175 nebulized local anesthetics 0.604885 pericardial sclerotherapy 0.657003 chest pain 0.622877 malignant pericardial effusions 0.808201 pericardial sclerosis. 0.657675 malignant pleural effusions 0.666328 pericardial effusions 0.86832 chest x-ray 0.605659 pericardial drainage 0.663513	CLICK HERE
1620	National Cancer Institute	Html	en	Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.	red blood cells 0.768748 cancer treatment 0.388453 blood -forming cells 0.422515 blast cells 0.38801 PDQ cancer information 0.4465 clinical trial search 0.417483 white blood cells 0.789303 myelodysplastic /myeloproliferative neoplasm 0.381874 abnormal blood cells 0.425458 clinical trials 0.736543 mature blood cells 0.494148 myelomonocytic leukemia 0.471388 chronic myelomonocytic leukemia 0.433936 cancer information summary 0.411963 clinical trial 0.54455 patients 0.384599 blood cells 0.912354 chronic myelogenous leukemia 0.426541 immature cells 0.400391 platelets 0.382322 NCI PDQ cancer 0.377587 supportive care 0.382497 Treatment Editorial Board 0.386238 treatment 0.557882	stored stem cells 0.41047 myeloid stem cell 0.393162 immature blood cells 0.507153 blood stem cell 0.390434 cancer cells 0.421289 lymphoid stem cell 0.393903 Easy bruising 0.397179 atypical CML 0.383221 treatment clinical trials 0.403674 blood stem cells 0.764143 National Cancer Institute 0.413265 normal cells 0.378893 juvenile myelomonocytic leukemia 0.471101 new treatment 0.442289 white blood cell 0.40841 healthy red blood 0.434016 bone marrow 0.568618 myelodysplastic/ myeloproliferative neoplasms 0.38491 cells slowly increases 0.413624 cancer clinical trials 0.423855 myelodysplastic/myeloproliferative neoplasm 0.393131 immature white blood 0.444308 treatment options 0.378048 leukemia cells 0.390336	CLICK HERE
1772	National Cancer Institute	Html	es	Complicaciones gastrointestinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del estreñimiento, la retención fecal, la obstrucción intestinal y la diarrea como complicaciones del cáncer o su tratamiento. Se discute el tratamiento de estos problemas.	Coggrave M 0.462328 Velasco A 0.461355 Ripamonti C 0.458109 Moehl Boatwright ML 0.451889 Curr Pain Headache 0.444995 self-expanding metallic stent 0.516659 diarrea aguda 0.471951 Rectal perforation following 0.463224 radiografía abdominal 0.448054 controlled trial with 0.449945 tracto gastrointestinal distal 0.449681 patients admitted 0.480057 intestinal maligna crónica 0.573598 fármacos causa dependencia 0.472502 malignant bowel 0.527918 Bazzocchi G 0.468893 analgésicos opioides 0.492661 or chemoradiation regimens 0.446129 determinados pacientes 0.452232 Pain Symptom Manage 0.66241 fecal impaction 0.534307 transanal irrigation versus 0.453674 Mosby Year Book 0.447131 Care Cancer 0.448621 fármacos alcaloides 0.46147	Dis Colon Rectum 0.550618 Thomas J 0.454566 Anderson Cancer Center 0.653069 anticolinérgicos opioides 0.50471 spinal cord-injured patients 0.45334 neuropatía autonómica 0.478269 transanal irrigation 0.61955 día expulsa ventosidades 0.465092 Cancer Care 0.446986 Krogh K 0.53282 ¿El paciente usa 0.521414 efecto secundario tardío 0.447263 MD Anderson Cancer 0.654313 retrospective review 0.463703 Clin North Am 0.519081 intestinal progresiva crónica 0.560422 Bruera E 0.519584 Suarez-Almazor M 0.462413 obstrucción mejora 0.544797 palliative care unit 0.529131 obstrucción intestinal aguda 0.896575 aceite mineral 0.990534 Med Clin North 0.445549 imaginología abdominal 0.451038	CLICK HERE
1926	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	células madre 0.33069 leucemia linfoblástica aguda 0.322509 siguientes afecciones 0.302348 hueso compacto 0.308819 neoplasias mieloides 0.302225 vía oral 0.301703 rayos x 0.301869 gen braf 0.305773 largo plazo 0.304831 célula madre mieloide 0.311776 National Cancer Institute 0.301791 siguientes riesgos 0.301225 células pilosas 0.98731 Instituto Nacional 0.306123 PDQ Tratamiento 0.305303	célula madre linfoide 0.305127 Linfocitos T 0.303214 siguientes problemas 0.302353 leucemia mielógena 0.31078 Drugs Approved 0.301713 Physician Data Query 0.306482 anticuerpo monoclonal rituximab 0.304903 anticuerpo monoclonal usa 0.304464 Hairy Cell Leukemia 0.302945 leucemia mieloide aguda 0.322517 siguientes enlaces 0.301398 célula madre 0.330149 células sanguíneas maduras 0.327581 ósea elabora células 0.315738	CLICK HERE
2073	National Cancer Institute	Html	es	Biopsia de ganglio linfático centinela	Describe el procedimiento de biopsia de ganglio linfático centinela, su uso para determinar la extensión, o estadio, del cáncer en el cuerpo, y los resultados de investigación sobre el uso de este tipo de biopsia en cáncer de seno y melanoma.	Surgical Adjuvant Breast 0.600625 Lancet Oncology 0.600394 falsa sensación 0.600322 American Medical Association 0.600457 Hunt KK 0.600275 excelente resultado 0.600374 Anderson SJ 0.600281 ganglio linfático centinela 0.999164 Selective Lymphadenectomy Trial 0.600594 Bowel Project 0.600314 células inmunitarias llamadas 0.601282 Julian TB 0.600295 Ballman KV 0.60032 linfocitos b 0.600438 Giuliano AE 0.600304 rara vez 0.60032 ganglios linfáticos centinelas 0.613287 sentinel node metastasis 0.600629 axillary dissection 0.600834 Instituto Nacional 0.602213	Krag DN 0.600307 Lyman GH 0.600292 Axillary dissection vs 0.600551 fase iii 0.601556 Surgeons Oncology Group 0.600619 ganglio centinela 0.636993 ecografía rutinaria 0.600317 pequeña incisión 0.600338 overall survival findings 0.600577 PubMed Abstract 0.601839 sentinel lymph 0.601172 Silbermins D 0.600275 with invasive breast 0.600626 Lymphatic mapping 0.600313 patients with 0.600887 linfadenectomía axilar 0.605014 Instituto Oncológico John 0.60052 Clinical Oncology 0.600393 NSABP B-32 0.600293	CLICK HERE
3517	National Cancer Institute	Html	en	Randomization and Bias in Cancer Clinical Trials	Information about randomization and bias in cancer clinical trials.	different treatments 0.635974 Single-blinded trials 0.587003 treatment 0.879587 instance 0.449169 simplest trial design 0.829657 human choices 0.621077 control group 0.779296 trial 0.855759 example 0.496876 points 0.446685 different health changes 0.763108 randomization 0.811688 bias 0.660255 Double-blinded trials 0.584527 clinical trials 0.60736 end 0.493376 group 0.945379 clinical trial 0.755171	phase 0.504191 new treatment 0.781754 process 0.451025 chance 0.58412 researchers 0.446538 patients 0.774398 trial results 0.587968 treatment trials 0.574174 groups 0.737104 investigational group 0.633981 people 0.445658 way 0.48098 healthier patients 0.602713 treatment group 0.70095 doctors 0.497874 unusual side effects 0.592351 sicker patients 0.596186 standard therapy 0.638086	CLICK HERE